Investing.com - Financial Markets Worldwide
Open in App

Alivus Life Sciences Ltd (ALIV)

NSE
Symbol
Exchange
Currency
ALIV·NSE·INR
ALIV·BSE·INR
Currency in INR
1,374.20
-5.10(-0.37%)
Closed·

ALIV Financial Summary

Key Ratios

P/E Ratio27.55
Price/Book4.98
Debt / Equity1.7%
Return on Equity18.36%
Dividend Yield0.36%
EBITDA7.88B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
2026
31/03
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aa21,232.1421,612.222,832.1423,868.8425,518.32
Gross Profit
aa.aaaa.aaaa.aaaa.aa10,555.311,143.712,432.9912,561.2714,111.82
Operating Income
aa.aaaa.aaaa.aaaa.aa5,789.266,007.576,221.356,237.967,224.67
Net Income
aa.aaaa.aaaa.aaaa.aa4,187.244,669.614,708.884,856.275,644.83
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aa24,710.0727,021.4728,504.1234,114.5339,828.97
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aa3,839.964,965.444,387.734,701.595,080.35
Total Equity
aa.aaaa.aaaa.aaaa.aa20,543.1221,382.0723,323.2228,173.7233,321.32
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aa3,756.23553.752,107.641,390.151,715.15
Cash from Operations
aa.aaaa.aaaa.aaaa.aa5,975.853,060.064,135.153,915.245,654.13
Cash from Investing
aa.aaaa.aaaa.aaaa.aa-1,222.28-1,467.47-1,164.83-6,156.45-5,701.53
Cash from Financing
aa.aaaa.aaaa.aaaa.aa-787.96-3,875.93-2,794.41-62.31-643.4
Net Change in Cash
aa.aaaa.aaaa.aaaa.aa3,965.61-2,283.34175.91-2,303.52-690.8
* In Millions of INR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 49.03%
Dividend Yield
0.36%
Industry Median 0.66%
Annualized payout
5.00
Paid unevenly
5-Years Growth
-
Growth Streak
Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1,432.25
(+4.22% Upside)

Earnings

Latest Release
Jul 30, 2026
EPS / Forecast
13.00 / --
Revenue / Forecast
6.4B / 6.68B
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Alivus Life Sciences's earnings for the latest quarter?

The Alivus Life Sciences EPS (TTM) is 49.03. Alivus Life Sciences reported sales of 6,404.14, net income of 1,600.76, and EPS of 13.00 for the latest quarter.

What was Alivus Life Sciences's net income for the latest quarter?

Alivus Life Sciences's net income for the latest quarter was 1,600.76.

How did Alivus Life Sciences's performance compare year-over-year in the latest quarter?

The company's revenue moved from 6,891.17 million INR in the previous quarter to 6,404.14 million INR in the latest quarter, and net income moved from 1,626.61 million INR to 1,600.76 million INR compared to the previous quarter.

What is Alivus Life Sciences's net profit margin on a TTM basis?

Alivus Life Sciences's trailing twelve months (TTM) net profit margin is 23.28%.

How does Alivus Life Sciences's debt to equity ratio compare to industry standards?

Alivus Life Sciences's total debt-to-equity ratio is 1.70%.

What is Alivus Life Sciences's return on investment on a TTM basis?

Alivus Life Sciences's trailing twelve months (TTM) return on investment (ROI) is 18.36%.

How has Alivus Life Sciences's total revenue grown this year?

Alivus Life Sciences's total revenue was 6,891.17 million INR in the previous quarter and 6,404.14 million INR in the latest quarter.

What is Alivus Life Sciences's gross margin on a TTM basis?

Alivus Life Sciences's trailing twelve months (TTM) gross margin is 59.42%%.

What was Alivus Life Sciences's revenue per share for the latest quarter?

Alivus Life Sciences's revenue per share for the latest quarter was 339.36.
Install Our App
Follow us
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.